Deborah Knoerzer

587 total citations
11 papers, 106 citations indexed

About

Deborah Knoerzer is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Deborah Knoerzer has authored 11 papers receiving a total of 106 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Deborah Knoerzer's work include Cancer Mechanisms and Therapy (2 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers) and Peptidase Inhibition and Analysis (2 papers). Deborah Knoerzer is often cited by papers focused on Cancer Mechanisms and Therapy (2 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers) and Peptidase Inhibition and Analysis (2 papers). Deborah Knoerzer collaborates with scholars based in United States and Italy. Deborah Knoerzer's co-authors include Bruce A. Berkowitz, Jane R. Connor, Hongmei Luan, Robin Roberts, Yasuki Ito, Thomas C. Hohman, Daniel Pacheco, Yunpeng Du, Timothy S. Kern and Channing J. Der and has published in prestigious journals such as Cancer Research, Diabetes and Investigative Ophthalmology & Visual Science.

In The Last Decade

Deborah Knoerzer

11 papers receiving 104 citations

Peers

Deborah Knoerzer
Yibo Gong China
Angela Cheng United States
Darrell Andrews Ireland
Yanping Yu China
Mark Gillies Australia
Rachel Juneau Canada
Shayma Jawad United States
Yangningzhi Wang China
Edward Dervan Ireland
Gudny A. Arnadottir Iceland
Yibo Gong China
Deborah Knoerzer
Citations per year, relative to Deborah Knoerzer Deborah Knoerzer (= 1×) peers Yibo Gong

Countries citing papers authored by Deborah Knoerzer

Since Specialization
Citations

This map shows the geographic impact of Deborah Knoerzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Knoerzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Knoerzer more than expected).

Fields of papers citing papers by Deborah Knoerzer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Knoerzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Knoerzer. The network helps show where Deborah Knoerzer may publish in the future.

Co-authorship network of co-authors of Deborah Knoerzer

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Knoerzer. A scholar is included among the top collaborators of Deborah Knoerzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Knoerzer. Deborah Knoerzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Buchbinder, Elizabeth I., Justine V. Cohen, Giuseppe Tarantino, et al.. (2024). A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma. Cancer Research Communications. 4(5). 1321–1327. 7 indexed citations
2.
3.
Grierson, Patrick, Benjamin Tan, Katrina S. Pedersen, et al.. (2022). Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma. The Oncologist. 28(2). e115–e123. 24 indexed citations
4.
Friedland, Julie C., Aaron U. Blackham, Alyson McIntosh, et al.. (2022). Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma. Melanoma Research. 32(4). 295–298. 6 indexed citations
5.
Linehan, W. Marston, et al.. (2022). Abstract 1057: Significant efficacy demonstrated with the combination of ulixertinib (ERK1/2 inhibitor) and CDK4/6 inhibitors in MAPK altered models. Cancer Research. 82(12_Supplement). 1057–1057. 2 indexed citations
6.
Knoerzer, Deborah, et al.. (2013). Therapeutic efficacy of Sunitinib and other broad spectrum receptor tyrosine kinase inhibitors (RTKI) in bleomycin-induced pulmonary fibrosis. Journal of Inflammation. 10(Suppl 1). P38–P38. 1 indexed citations
7.
8.
Berkowitz, Bruce A., Robin Roberts, Hongmei Luan, et al.. (2005). Drug Intervention Can Correct Subnormal Retinal Oxygenation Response in Experimental Diabetic Retinopathy. Investigative Ophthalmology & Visual Science. 46(8). 2954–2954. 18 indexed citations
9.
Berkowitz, Bruce A., Hongmei Luan, Daniel Pacheco, et al.. (2004). Regulation of the Early Subnormal Retinal Oxygenation Response in Experimental Diabetes by Inducible Nitric Oxide Synthase. Diabetes. 53(1). 173–178. 35 indexed citations
10.
Knoerzer, Deborah, et al.. (2003). Serum Matrix Metalloproteinase Levels and Activities in Patients With Glaucoma. Investigative Ophthalmology & Visual Science. 44(13). 102–102. 1 indexed citations
11.
Agrawal, Sudhir, Ekambar R. Kandimalla, Yu Dong, et al.. (2001). Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides. International Journal of Oncology. 18(5). 1061–9. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yibo Gong Breakdown of academic impact, for papers by Angela Cheng Breakdown of academic impact, for papers by Darrell Andrews Breakdown of academic impact, for papers by Yanping Yu Breakdown of academic impact, for papers by Mark Gillies Breakdown of academic impact, for papers by Rachel Juneau Breakdown of academic impact, for papers by Shayma Jawad Breakdown of academic impact, for papers by Yangningzhi Wang Breakdown of academic impact, for papers by Edward Dervan Breakdown of academic impact, for papers by Gudny A. Arnadottir
Rankless by CCL
2026